- In August 2024, Abbott and Medtronic announced a global collaboration to integrate Abbott’s FreeStyle Libre continuous glucose monitors (CGMs) with Medtronic’s insulin delivery systems. In this partnership, the aim is to create a comprehensive system combining Abbott’s CGM technology with Medtronic's advanced insulin delivery solutions, such as the MiniMed 780G and smart insulin pens such as the InPen. In addition, Medtronic plans to continue using its own CGM products, including the Guardian 4 and Simplera platforms, as part of its diverse CGM portfolio
- In June 2024, Aptar Digital Health, a global leader in digital health solutions including Software as a Medical Device (SaMD) and digital Patient Support Programs, announced a collaboration with SHL Medical, a top provider of advanced drug delivery systems such as autoinjectors and pen injectors. In this partnership, the goal is to enhance SHL Medical’s connected device technologies by integrating Aptar Digital Health’s SaMD platform, creating comprehensive solutions for managing disease in patients using injectable therapies
- In October 2022, Merck KGaA, the company expanded its collaboration with Biocorp to develop a Bluetooth-enabled clip-on device tailored for one of its drug delivery systems. In this extended partnership, the focus is on enhancing connectivity and monitoring in drug administration
- In February 2022, Aptar Pharma, the company introduced HeroTracker® Sense, a novel digital solution that transforms a standard metered dose inhaler (pMDI) into a smart, connected healthcare device. In this innovation, the aim is to enhance respiratory health management through real-time data tracking and patient engagement.
- In April 2021, AARDEX Group, based in Belgium and a leader in medication adherence solutions, the company partnered with Pill Connect Ltd, an English company known for designing and manufacturing advanced medical devices for oral medication dispensing. In this strategic partnership, AARDEX’s Medication Event Monitoring System (MEMS) is connected with Pill Connect’s add-on drug delivery solutions, offering significant potential to improve patient adherence and treatment outcomes
Frequently Asked Questions
The market is segmented based on Segmentation, By Product Type (Connected Sensors, Connected Inhaler Sensors, Connected Injection Sensors, Integrated Connected Devices, Integrated Inhalation Devices, and Integrated Injection Devices), Technology (Near Field Communication (NFC), Bluetooth, and Other), End User (Healthcare Providers, Homecare, and Hospitals) – Industry Trends and Forecast to 2032
.
The Global Connected Drug Delivery Devices Market size was valued at USD 500.71 USD Million in 2024.
The Global Connected Drug Delivery Devices Market is projected to grow at a CAGR of 16.69% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
